AMD is the leading cause of reduced visual acuity in patients over 65 years of age, and, despite the development of new anti-VEGF antibodies to counteract neovascularization (i.e., ranibizumab, bevacizumab, aflibercept, etc.)[2], treatment failure still occurs due to side effects and resistance. Here, VEGFA is linked to age-related macular degeneration.